Olympus’ new Chief Executive Officer Bob White is shaking up the Tokyo-based medical devices maker after a difficult period that included the ouster of his predecessor in a drug scandal.

Five months into the role, White unveiled a plan to cut about 2,000 jobs — about 7% of its global work force — and an overhaul of the company’s region-centric structure to streamline operations and boost productivity. Olympus is also reviewing its supply chain, as it aims to cut costs by ¥24 billion ($157 million).

Olympus had duplications “everywhere” — from finance and quality control to marketing and human resources — due to its regional setup, White stated in an interview. “We hadn’t globalized our core functions,” he said. “We just had a lot of people doing really good work, but they were doing fragmented work.”

White took over with Olympus in turmoil following the sudden exit of ex-CEO Stefan Kaufmann last year, while the company also faces warnings from U.S. regulators over product quality control. Shares of Olympus have fallen about 21% this year, compared to an 18% rise in the benchmark Topix index.

Operating profit for the six months ended September fell 35% to ¥46 billion from a year earlier, Olympus said Friday after markets in Tokyo had closed. Sales dropped 4.2% to ¥454.4 billion. The company reiterated it expects full-year profit to fall 16% to ¥136 billion, slightly above analyst estimates.

The company is moving to a leaner, divisional model with clearer accountability, White said. Olympus is targeting 3% annual sales growth by fiscal 2027.

About 70% of the company’s suppliers are based in Japan, even though the majority of its sales come from the United States and Europe. White said Olympus will look at the best options for location, resiliency and cost.

Olympus is also trying to regain competitiveness in China, White said. With government policy favoring locally-made products, the company is localizing production, refining its strategy and strengthening ties with the authorities to adapt to the new environment, he said.

In the U.S., Olympus expects some inspections by regulators to be done by the end of the year, White said. The Food and Drug Administration warned health-care providers in June about importing certain medical devices manufactured in Japan by Olympus, including some endoscopes and machines used to wash them.